Publication | Closed Access

Chitosan-stabilized selenium nanoparticles alleviate cardio-hepatic damage in type 2 diabetes mellitus model via regulation of caspase, Bax/Bcl-2, and Fas/FasL-pathway

NanomedicineEngineeringSelenium DeficiencyMedicineLiver PhysiologyDiabetesType 2Nano-drug DeliveryBiomedical EngineeringDiabetes Mellitus ModelPharmacologyChitosan-stabilized Selenium Nanoparticles